Bill Huizenga Repeatedly Voted Against Protecting And Expanding The Affordable Care Act, Including For People With Pre-Existing Conditions
May 2019: Huizenga Voted Against The Protecting Americans With Preexisting Conditions Act, Which Would Nullify Trump Administration Guidance Allowing States To Make Major Changes To Their ACA Markets
May 2019: Huizenga Voted Against The Protecting Americans With Preexisting Conditions Act, Prohibiting Federal Departments From Exempting State Health Care Plans From Federal Requirements Under The ACA. In May 2019, Huizenga voted against: “Passage of the bill that would prohibit the Health and Human Services and Treasury departments from taking any action to implement or enforce their October 2018 guidance regarding criteria for evaluating Section 1332 state health care plan waivers under the 2010 health care overhaul, and would prohibit the departments from effectively reissuing the guidance. Section 1332 waivers exempt state health care plans from certain federal requirements under the Affordable Care Act, including requirements related to qualified health plans, tax credits, and individual and employer mandates. To be eligible for such waivers, proposed state plans are required to provide care to a ‘comparable number’ of residents that is ‘as comprehensive’ and ‘as affordable’ as would otherwise be provided under the ACA. The October 2018 guidance modifies guidelines for considering waiver applications, emphasizing that a proposed state health care plan should be evaluated based on the number of residents that would have ‘access’ to comparable coverage under the plan, as opposed to the number of residents that purchase such coverage.” The motion was agreed to by a vote of 230-183. [HR 986, Vote #196, 5/9/19; CQ, 5/9/19]
- The Bill Would Nullify Trump Administration Guidance Allowing States To Make Major Changes To Their Affordable Care Act Markets. “The bill would nullify a Trump administration guidance that would allow states to ask for waivers to make major changes to their Obamacare markets. The Centers for Medicare & Medicaid Services laid out in November four examples of what states could request -- opening the door for people to use subsidies to buy coverage outside the Obamacare exchanges. This would include short-term health insurance plans that can reject people with pre-existing conditions or charge them higher premiums. The Trump administration last year made these policies more attractive by extending their terms to just under a year, instead of three months.” [CNN, 5/9/19]
May 2019: Huizenga Voted Against The Strengthening Health Care And Lowering Prescription Drug Costs Act Which Would Expand And Strengthen Affordable Care Act Coverage
May 2019: Huizenga Voted Against The Strengthening Health Care And Lowering Prescription Drug Costs Act. In May 2019, Huizenga voted against: “Passage of the bill, as amended, that comprises a package of measures related to the development and market entry of generic drugs and a package of measures related to enrollment in and federal funding to support Affordable Care Act health insurance marketplaces. Title I of the bill includes provisions intended to facilitate the development and market entry of generic and biosimilar drug products. Specifically, it would allow the Food and Drug Administration to approve a subsequent company's application to manufacture a generic drug in cases where an initial company has applied but not received final FDA approval to introduce the drug after 30 months; approval of the subsequent application would trigger a 180-day exclusivity period for sale of the generic drug by the initial applicant company, after which point other generic versions could enter the market. It would prohibit generic and brand-name drug manufacturers from entering into agreements in which brand-name manufacturers pay to delay entry of a generic drug into the market, and it would authorize the Federal Trade Commission to issue penalties and initiate civil actions to enforce the prohibition. It would allow generic drug manufacturers to bring civil action against the license holder for a brand-name drug if the license holder does not provide ‘sufficient quantities’ of samples of the brand-name drug on ‘commercially reasonable, market-based terms;’ it would also outline certain affirmative legal defenses for defendants and certain terms for legal remedies in the case of a successful suit. Title II of the bill includes several provisions intended to facilitate enrollment in and provide funding and support for state- and federally-operated health insurance marketplaces under the Affordable Care Act. Specifically, it would authorize $200 million in grant funding for states to establish and operate state-based ACA health insurance marketplaces. It would authorize $100 million for Health and Human Services Department consumer outreach and educational activities related to ACA marketplace plans. It would authorize $100 million for the HHS ‘navigator’ program, which funds certified entities to help individuals enroll in qualified plans, and would make certain modifications to the duties and selection of navigators. It would prohibit the HHS, Treasury, and Labor departments from taking any action to implement or enforce an August 2018 rule that effectively extends the maximum duration of coverage for short-term, limited-duration health insurance plans, which are not required to meet ACA patient protection requirements. As amended, the bill would authorize $25 million annually in grant funding for the ACA navigator program in state-based marketplaces and include a number of additional requirements related to outreach and education programs by navigators and by HHS.” The bill passed 234-183. [HR 987, Vote #214, 5/16/19; CQ, 5/16/19]
- The Bill Included Money For States To Set Up ACA Insurance Marketplaces, Restored Funding For ACA Enrollment And Outreach, And Repealed The Expansion Of Short Term Insurance Plans. “Democrats have paired those policies with a few proposals to shore up Obamacare: providing money for states to set up their own insurance marketplaces[;] restoring funding for ACA enrollment outreach and support cut by the Trump administration[;] repealing President Donald Trump’s expansion of skimpy ‘short-term’ insurance plans” [Vox, 5/13/19]
- HEADLINE: “House Passes Drug Pricing Bills Paired With Obamacare Fixes” [Politico, 5/16/19]
January-June 2019: Huizenga Voted Repeatedly To Allow The Trump Administration’s Legal Campaign Against The Affordable Care Act To Move Forward
January 2019: Huizenga Voted Against Authorizing House Intervention Into The Texas Court Case That Found The Affordable Care Act Unconstitutional. In January 2019, Huizenga voted against: “Adoption of the resolution that would establish the rules of the House for the 116th Congress. Title III of the resolution would authorize the speaker, on behalf of the House of Representatives, to intervene in the Texas court case that found the 2010 healthcare law unconstitutional and other cases related to the law. It would also direct the Office of General Counsel to represent the House in any such litigation.” The resolution was adopted 235-192. [H Res 6, Vote #19, 1/09/19; CQ, 1/9/19]
- HEADLINE: “House Democrats Vote To Defend ACA In Court — And Jam Republicans.” [Washington Post, 1/3/19]
April 2019: Huizenga Voted Against Condemning The Trump Administration’s Legal Campaign Against The Affordable Care Act. In April 2019, Huizenga voted against: “Passage of the resolution that would express the sense of the House of Representatives that the Trump administration's stance on invalidating the 2010 health care law is ‘unacceptable’ and that the Justice Department should protect individuals with preexisting conditions, individuals who pay high costs for prescription drugs, and individuals who ‘gained health insurance coverage since 2014.’ The resolution would recommend that the department reverse its position in the case of Texas v. United States.” The resolution passed 240 to 186. [H Res 271, Vote #146, 4/3/19; CQ, 4/3/19]
- HEADLINE: “House Votes To Condemn Trump Administration’s Opposition To ACA.” [Jurist.org, 4/4/19]
June 2019: Huizenga Voted Against An Amendment Prohibiting Justice Department Funds From Being Used To Argue The Affordable Care Act Was Unconstitutional. In June 2019, Huizenga voted against: “Underwood, D-Ill., amendment that would prohibit the use of funds provided by the bill for the Justice Department to argue that the Patient Protection and Affordable Care Act is unconstitutional or invalid in any litigation to which the U.S. is a party.” The motion was adopted by a vote of 238-194. [HR 3055, Vote #374, 6/20/19; CQ, 6/20/19]